

PE/Cyanine7 anti-mouse F4/80 Antibody

Catalog# / Size	123113 / 25 µg 123114 / 100 µg
Clone	BM8
Regulatory Status	RUO
Other Names	EMR1, Ly71
Isotype	Rat IgG2a, κ
Description	F4/80 is a 160 kD glycoprotein. It is characterized as a member of the epidermal growth factor (EGF)-transmembrane 7 (TM7) family. F4/80, also known as EMR1 or Ly71, has been widely used as a murine macrophage marker, which is expressed on the majority of tissue macrophages including peritoneal macrophages, macrophages in lung, gut, thymus and red pulp of spleen (but not on the macrophages located in T cell areas of the spleen, lymph node and Peyer's patch), Kuffer cells, Langerhans cells, and bone marrow stromal cells. F4/80 has also been shown on a subset of dendritic cells. The biological ligand of F4/80 has not been identified, but it has been reported that F4/80 is required for induction of CD8 ⁺ T cell-mediated peripheral tolerance.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Murine macrophages
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes	Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections ^{1,2} and formalin-fixed paraffin-embedded sections ^{6,7} , Western blotting, and spatial biology (IBEX) ^{12,13} .
Additional Product Notes	BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References	<ol style="list-style-type: none"> Schaller E, <i>et al.</i> 2002. <i>Mol. Cell. Biol.</i> 22:8035. (IHC) Stevceva L, <i>et al.</i> 2001. <i>BMC Clin Pathol.</i> 1:3. (IHC) Kobayashi M, <i>et al.</i> 2008. <i>J. Leukoc. Biol.</i> 83:1354. PubMed Poeckel D, <i>et al.</i> 2009. <i>J. Biol Chem.</i> 284:21077. PubMed Glass AM, <i>et al.</i> 2013. <i>J. Immunol.</i> 190:4830. PubMed Koehm S, <i>et al.</i> 2007. <i>J. Allergy Clin. Immunol.</i> 120:570. (IHC)
(PubMed link indicates BioLegend citation)	

7. Rankin AL, et al. 2010. *J. Immunol.* 184:1526. (IHC)
8. Sasi SP, et al. 2014. *J Biol Chem.* 289:14178. [PubMed](#)
9. Thakus VS, et al. 2014. *Toxicol Lett.* 230:322. [PubMed](#)
10. Watson NB, et al. 2015. *J Immunol.* 194:2796. [PubMed](#)
11. Hirakawa H, et al. 2015. *PLoS One.* 10:119360. [PubMed](#)
12. Radtke AJ, et al. 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
13. Radtke AJ, et al. 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Doni A, et al. 2015. *J Exp Med.* 212:905. [PubMed](#)
2. Orberg E, et al. 2016. *Mucosal Immunol.* 10.1038/mi.2016.53. [PubMed](#)
3. Michela Miani et al. 2018. *Cell metabolism.* 28(4):557-572. [PubMed](#)
4. Hou X, et al. 2020. *Cell Reports.* 28(1):172-189.e7.. [PubMed](#)
5. Siervo F, et al. 2017. *Immunity.* 47:374. [PubMed](#)
6. Fan G, et al. 2021. *Cell Death Dis.* 12:73. [PubMed](#)
7. Garo LP, et al. 2021. *Nat Commun.* 12:2419. [PubMed](#)
8. Su Y, et al. 2022. *J Hematol Oncol.* 15:99. [PubMed](#)
9. Aggen DH, et al. 2020. *Clin Cancer Res.* [PubMed](#)
10. Cornax I, et al. 2021. *Microorganisms.* 9:00. [PubMed](#)
11. Lauterbach MA, et al. 2020. *Immunity.* 51(6):997-1011.e7.. [PubMed](#)
12. Poh AR, et al. 2017. *Cancer Cell.* 31:563. [PubMed](#)
13. Fachi JL et al. 2019. *Cell reports.* 27(3):750-761. [PubMed](#)
14. Yonemitsu K, et al. 2022. *Sci Rep.* 12:12007. [PubMed](#)
15. Schloss MJ, et al. 2022. *Nat Immunol.* 23:605. [PubMed](#)
16. Li X, et al. 2022. *Nat Commun.* 13:2794. [PubMed](#)
17. Dando SJ, et al. 2021. *Invest Ophthalmol Vis Sci.* 62:10. [PubMed](#)
18. Tripathi H, et al. 2020. *J Mol Cell Cardiol.* 149:95. [PubMed](#)
19. Delvecchio FR, et al. 2021. *Cell Mol Gastroenterol Hepatol.* 12:1543. [PubMed](#)
20. Saxena A, et al. 2013. *J Immunol.* 191:4838. [PubMed](#)
21. Giordano C, et al. 2014. *Hum Mol Genet.* [PubMed](#)
22. Chou YJ, et al. 2020. *Sci Rep.* 10:8422. [PubMed](#)
23. Sadek J, et al. 2021. *EMBO Mol Med.* 13:e13591. [PubMed](#)
24. Frank AC, et al. 2021. *Theranostics.* 11:7570. [PubMed](#)
25. Rodriguez-Garcia A, et al. 2021. *Nat Commun.* 12:877. [PubMed](#)
26. Kesavan R, et al. 2021. *Int J Mol Sci.* 22: [PubMed](#)
27. Sasse C, et al. 2022. *Pathogens.* 11: [PubMed](#)
28. Adachi Y, et al. 2022. *Nat Commun.* 13:5117. [PubMed](#)
29. Weigert A, et al. 2022. *Nat Commun.* 13:6078. [PubMed](#)
30. Allegrezza M, et al. 2016. *Cancer Res.* 76: 6253 - 6265. [PubMed](#)
31. Coppo M, et al. 2016. *Nat Commun.* 7:12254. [PubMed](#)
32. Shang W, et al. 2019. *J Diabetes Res.* 2019:5641271. [PubMed](#)
33. Shikatani EA et al. 2019. *Cell Rep.* 27(8):2304-2312. [PubMed](#)
34. Andreas N, et al. 2021. *Arthritis Res Ther.* 23:222. [PubMed](#)
35. Huard A, et al. 2021. *J Immunol.* 206:1058. [PubMed](#)
36. Achmus L, et al. 2020. *Front Neurol.* 11:577971. [PubMed](#)
37. Nagatake T, et al. 2022. *Mucosal Immunol.* 15:289. [PubMed](#)
38. Cheng G, et al. 2021. *iScience.* 24:102673. [PubMed](#)
39. Patnode M, et al. 2013. *J Biol Chem.* 288:26533. [PubMed](#)
40. Starkl P, et al. 2020. *Immunity.* 53(4):793-804.e9. [PubMed](#)
41. Damal Villivalam S, et al. 2020. *Nat Commun.* 4313:11. [PubMed](#)
42. Han Y et al. 2019. *Cell reports.* 27(3):835-846. [PubMed](#)
43. Currier MA, et al. 2017. *Oncotarget.* 8:17412. [PubMed](#)
44. Park JA, et al. 2021. *J Hematol Oncol.* 14:142. [PubMed](#)
45. Sive J, et al. 2015. *Leukemia.* [PubMed](#)
46. Sharma S, et al. 2015. *J Immunol.* 194:5529. [PubMed](#)
47. Fujikura D, et al. 2013. *PLoS One.* 8:e55321. [PubMed](#)
48. Koh EH, et al. 2018. *Diabetes.* 67(12). [PubMed](#)
49. Luo W, et al. 2019. *Mol Med Rep.* 20:1007. [PubMed](#)
50. Shimoda A, et al. 2017. *Biochem Biophys Res Commun.* 10.1016/j.bbrc.2017.07.126. [PubMed](#)
51. Hao F, et al. 2021. *Proc Natl Acad Sci U S A.* 118: [PubMed](#)
52. Stutchfield B, et al. 2015. *Gastroenterology.* 149: 1896-1909.e14. [PubMed](#)
53. Jondle C, et al. 2016. *J Immunol.* 196: 3088-3096. [PubMed](#)
54. Szafran BN, et al. 2021. *Chemical Research in Toxicology.* 34(6):1556-1571. [PubMed](#)
55. Maston LD, et al. 2017. *Am J Physiol Lung Cell Mol Physiol.* 312:L609. [PubMed](#)
56. Zhang S, et al. 2019. *Cell Metab.* 29:443. [PubMed](#)
57. Qu J, et al. 2018. *J Immunol Res.* 2018:7519856. [PubMed](#)
58. Terashima Y, et al. 2020. *Nat Commun.* 11:609. [PubMed](#)
59. Cheng K, et al. 2021. *Nat Commun.* 12:2041. [PubMed](#)
60. Wu X, et al. 2021. *Elife.* 10: [PubMed](#)
61. Roy R, et al. 2022. *Elife.* 11: [PubMed](#)
62. Tay S, et al. 2014. *J Immunol.* 193:2087. [PubMed](#)
63. Linde N, et al. 2018. *Nat Commun.* 9:21. [PubMed](#)
64. Xiao Y, et al. 2022. *Clin Transl Med.* 12:e1071. [PubMed](#)
65. Smith AS, et al. 2022. *J Immunother Cancer.* 10: [PubMed](#)
66. Tomlinson KL, et al. 2021. *Nat Commun.* 12:1399. [PubMed](#)
67. Wu MY, et al. 2021. *Autophagy.* 17:1096. [PubMed](#)
68. Kornstädt L, et al. 2021. *Front Immunol.* 11:607048. [PubMed](#)
69. Ajina R, et al. 2021. *Cancer Immunol Res.* 9:386. [PubMed](#)
70. Weber G, et al. 2014. *J Exp Med.* 211:1243. [PubMed](#)

71. Francis M, *et al.* 2017. *Toxicol Sci.* 155(1):182-195. [PubMed](#)
72. Wang ECE, *et al.* 2019. *Cell Stem Cell.* 24:654. [PubMed](#)
73. Hulsmans M *et al.* 2017. *Cell.* 169(3):510-522. [PubMed](#)
74. Zheng Z, *et al.* 2020. *Cell Death Dis.* 0.684722222. [PubMed](#)
75. Morimoto A, *et al.* 2021. *Nat Commun.* 12:2136. [PubMed](#)
76. Lu X, *et al.* 2020. *Sci Transl Med.* 12:. [PubMed](#)
77. Russler-Germain EV, *et al.* 2021. *Elife.* 10:. [PubMed](#)
78. Ganguly K, *et al.* 2022. *Front Immunol.* 13:930449. [PubMed](#)
79. Xu Z, *et al.* 2020. *Cancer Immunol Res.* 1354:8. [PubMed](#)
80. Brigas HC, *et al.* 2021. *Cell Reports.* 36(9):109574. [PubMed](#)
81. Volberding PJ, *et al.* 2021. *Cell Reports.* 35(8):109160. [PubMed](#)
82. Mojumdar K, *et al.* 2014. *EMBO Mol Med.* 6:1476. [PubMed](#)
83. Torroella-Kouri M, *et al.* 2009. *Cancer Res.* 69:4800. [PubMed](#)
84. Frodermann V, *et al.* 2019. *Nat Med.* 25:1761. [PubMed](#)
85. Xu X, *et al.* 2018. *Cell.* 175:1336. [PubMed](#)
86. Oertel S, *et al.* 2017. *Cell Mol Life Sci.* 10.1007/s00018-017-2518-9. [PubMed](#)
87. Zhao X, *et al.* 2022. *Nat Protoc.* 17:2240. [PubMed](#)
88. Yong L, *et al.* 2022. *Nat Commun.* 13:4255. [PubMed](#)
89. Golden TN, *et al.* 2022. *Front Pharmacol.* 12:761496. [PubMed](#)
90. Garland KM, *et al.* 2021. *Front Immunol.* 12:753472. [PubMed](#)
91. Reinfeld BI, *et al.* 2021. *Nature.* 593:282. [PubMed](#)
92. Chiu Y, *et al.* 2014. *J Immunol.* 193:2207. [PubMed](#)
93. Hamilton J, *et al.* 2015. *J Immunol.* 194:5022. [PubMed](#)
94. Mangum L, *et al.* 2016. *Toxicol Sci.* 150: 169 - 177. [PubMed](#)
95. Wanner-Seleznik GM, *et al.* 2020. *Immunohorizons.* 0.644444444. [PubMed](#)
96. Tripathi H, *et al.* 2020. *Stem Cell Rev Rep.* 0.953472222. [PubMed](#)
97. Engler AE, *et al.* 2020. *Cell Reports.* 33(13):108553. [PubMed](#)
98. Deerhake ME, *et al.* 2021. *Immunity.* 54(3):484-498.e8. [PubMed](#)
99. Lim CX, *et al.* 2020. *Cell Rep.* 3793:30. [PubMed](#)
100. Chung L *et al.* 2018. *Cell host & microbe.* 23(2):203-214. [PubMed](#)
101. Medler TR *et al.* 2018. *Cancer cell.* 34(4):561-578. [PubMed](#)
102. Xiong X *et al.* 2019. *Mol Cell.* 75(3):644-660. [PubMed](#)
103. Alameh MG, *et al.* 2021. *Immunity.* 54:2877. [PubMed](#)
104. Aktories P, *et al.* 2022. *Cell Rep Methods.* 2:100260. [PubMed](#)
105. Park HB, *et al.* 2020. *Nat Microbiol.* 1319:5. [PubMed](#)
106. Li C, *et al.* 2021. *Cell Metabolism.* 33(8):1610-1623.e5. [PubMed](#)
107. Yamakawa D, *et al.* 2021. *Cell Reports.* 34(10):108817. [PubMed](#)
108. Ren Y, *et al.* 2020. *Stem Cell Res Ther.* 0.743055556. [PubMed](#)
109. Alonso-Herranz L, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
110. Maisel D, *et al.* 2016. *PLoS One.* 11: 0159716. [PubMed](#)
111. Kim P, *et al.* 2015. *Infect Immun.* 83: 2992 - 3002. [PubMed](#)
112. Ballet R, *et al.* 2014. *PLoS Pathog.* 10:1004550. [PubMed](#)
113. Liu Z, *et al.* 2020. *Cell.* 178(6):1509-1525.e19. [PubMed](#)
114. Choi EW, *et al.* 2020. *Sci Rep.* 10:12001. [PubMed](#)
115. Yamada KJ, *et al.* 2020. *PLoS Pathog.* 16:e1008354. [PubMed](#)
116. Sun P, *et al.* 2022. *Nat Commun.* 13:6562. [PubMed](#)
117. Pathania AS, *et al.* 2022. *Mol Ther Oncolytics.* 25:308. [PubMed](#)
118. Bachy S, *et al.* 2022. *iScience.* 25:103758. [PubMed](#)
119. Anderson AE, *et al.* 2022. *NPJ Regen Med.* 7:6. [PubMed](#)
120. Maulloo CD, *et al.* 2021. *Front Immunol.* 12:714842. [PubMed](#)
121. Ahn D, *et al.* 2021. *Cell Reports.* 35(9):109196. [PubMed](#)
122. Efremova M, *et al.* 2018. *Nat Commun.* 9:32. [PubMed](#)
123. Su W *et al.* 2019. *Cancer Cell.* 36(2):139-155. [PubMed](#)
124. Quenum Zangbede FO, *et al.* 2018. *J Neurosci.* 38:6737. [PubMed](#)
125. Roy AG, *et al.* 2021. *Int J Mol Sci.* 22:. [PubMed](#)
126. Zeng Q, *et al.* 2022. *iScience.* 25:105151. [PubMed](#)
127. Li J, *et al.* 2020. *FASEB J.* 34:3091. [PubMed](#)
128. Hirata SI, *et al.* 2020. *Allergy.* 75:1939. [PubMed](#)
129. Heim CE, *et al.* 2020. *Nature Microbiology.* 5(10):1271-1284. [PubMed](#)
130. Tozuka M, *et al.* 2016. *J Dermatol Sci.* 82: 38-45. [PubMed](#)
131. Sharif O, *et al.* 2013. *J Immunol.* 190:5640. [PubMed](#)
132. Song M, *et al.* 2013. *Am J Pathol.* 182:1308. [PubMed](#)
133. Cai B, *et al.* 2020. *Cell Metabolism.* 31(2):406-421.e7. [PubMed](#)
134. Nabet BY *et al.* 2017. *Cell.* 170(2):352-366. [PubMed](#)
135. Ponzetta A, *et al.* 2020. *Cell.* 178(2):346-360.e24. [PubMed](#)
136. Nagatake T, *et al.* 2018. *J Allergy Clin Immunol.* 142:470. [PubMed](#)
137. Vasamsetti SB, *et al.* 2018. *Immunity.* 49:93. [PubMed](#)
138. Chu LH, *et al.* 2018. *Nat Commun.* 9:996. [PubMed](#)
139. Matsumura T, *et al.* 2022. *Nat Commun.* 13:7064. [PubMed](#)
140. Cheng HW, *et al.* 2022. *Nat Commun.* 13:2027. [PubMed](#)
141. Stevenson ER, *et al.* 2022. *J Pharmacol Exp Ther.* 382:356. [PubMed](#)
142. Baranwal G, *et al.* 2021. *Physiol Rep.* 9:e15094. [PubMed](#)
143. Mendelsohn AC, *et al.* 2020. *Am J Physiol Cell Physiol.* 319:C997. [PubMed](#)
144. Fujii T, *et al.* 2021. *Bone Res.* 9:4. [PubMed](#)
145. INAGAWA H, *et al.* 2016. *In Vivo.* 30: 205 - 211. [PubMed](#)
146. Wedekind MF, *et al.* 2021. *iScience.* 24(7):102759. [PubMed](#)
147. Clemente C, *et al.* 2018. *Nat Commun.* 9:910. [PubMed](#)
148. Laban H, *et al.* 2018. *J Cell Biol.* 217:1503. [PubMed](#)
149. Li C, *et al.* 2018. *Cell.* 174:285. [PubMed](#)
150. Nalbandian A, *et al.* 2017. *Inflammation.* 40:21:00. [PubMed](#)

151. Zhao Y, *et al.* 2020. *Immunity*. 51(6):1059-1073.e9.. [PubMed](#)
152. Fletcher P, *et al.* 2021. *J Toxicol Environ Health A*. 84:152. [PubMed](#)
153. Njock MS, *et al.* 2022. *J Extracell Vesicles*. 11:e12228. [PubMed](#)
154. Dallari S, *et al.* 2021. *Cell Host Microbe*. 29(6):1014-1029.e8. [PubMed](#)
155. Yun H, *et al.* 2020. *Immunity*. 53(5):1050-1062.e5. [PubMed](#)
156. Chan M, *et al.* 2013. *J Cell Sci*. 126:3948. [PubMed](#)
157. Muchenditsi A, *et al.* 2017. *Am J Physiol Gastrointest Liver Physiol*. 313:G39. [PubMed](#)
158. Gracyzyk JP *et al.* 2017. *Cell host & microbe*. 22(5):678-687 . [PubMed](#)
159. Clemente-Casares X, *et al.* 2017. *Immunity*. 47:974. [PubMed](#)
160. Zhu K, *et al.* 2022. *EMBO Rep*. 23:e54499. [PubMed](#)
161. Rao L, *et al.* 2020. *Nat Commun*. 11:4909. [PubMed](#)
162. Bell CR, *et al.* 2022. *Nat Commun*. 13:2063. [PubMed](#)
163. Montes de Oca M, *et al.* 2016. *PLoS Pathog*. 12: 1005398. [PubMed](#)
164. Senatus L, *et al.* 2020. *JCI Insight*. 5:00. [PubMed](#)
165. Urbanska AM, *et al.* 2020. *Cancer Biother Radiopharm*. 35:459. [PubMed](#)
166. Frank AC, *et al.* 2019. *Nat Commun*. 10:1135. [PubMed](#)
167. Zhang C, *et al.* 2018. *Cell Res*. 28:323. [PubMed](#)
168. Yoshida H, *et al.* 2019. *Cell*. 176:897. [PubMed](#)
169. Hoyer FF, *et al.* 2020. *Immunity*. 51(5):899-914.e7.. [PubMed](#)
170. Zhang Z, *et al.* 2020. *Nature*. 579:415. [PubMed](#)
171. Zhang L, *et al.* 2021. *Front Mol Biosci*. 8:647647. [PubMed](#)
172. Bonavita E, *et al.* 2020. *Immunity*. 1215:53. [PubMed](#)
173. Zhang L, *et al.* 2020. *Cell*. 442:181. [PubMed](#)
174. Sangaletti S, *et al.* 2021. *iScience*. 24(6):102510. [PubMed](#)
175. Sheng J, *et al.* 2021. *eLife*. 10:00. [PubMed](#)
176. Martins R, *et al.* 2016. *Nat Immunol*. 17:1361-1372. [PubMed](#)
177. Kwon H, Kim S 2016. *Cell Death Dis*. 7:22285. [PubMed](#)
178. Kong P, *et al.* 2013. *Am J Physiol Heart Circ Physiol*. 305:1363. [PubMed](#)
179. Fransén Pettersson N, *et al.* 2018. *PLoS One*. 13:e0203228. [PubMed](#)
180. Gundra UM, *et al.* 2017. *Nat Immunol*. 1.195833333. [PubMed](#)
181. Fan HH, *et al.* 2021. *Methods Mol Biol*. 2276:203. [PubMed](#)
182. Dye BR, *et al.* 2020. *Biomaterials*. 234:119757. [PubMed](#)
183. Bajracharya B, *et al.* 2022. *Biomed Res Int*. 2022:9928362. [PubMed](#)
184. Chavkin NW, *et al.* 2021. *J Am Heart Assoc*. 10:e019904. [PubMed](#)
185. Aguado B, *et al.* 2015. *Sci Rep*. 5: 17566. [PubMed](#)
186. Hall JA, *et al.* 2020. *Cell Metabolism*. 32(4):665-675.e6. [PubMed](#)
187. Li S, *et al.* 2017. *Applied Materials & Interfaces*. 10.1021/acsami.7b03160. [PubMed](#)
188. Sadtler K, *et al.* 2017. *Tissue Eng Part A*. 23:1044. [PubMed](#)
189. Petriello MC, *et al.* 2018. *Toxicol Sci*. 162:548. [PubMed](#)
190. Liu Z, *et al.* 2020. *STAR Protoc*. 1:100029. [PubMed](#)
191. Ramavath NN, *et al.* 2021. *Front Immunol*. 12:786680. [PubMed](#)
192. Shue YT, *et al.* 2022. *Nat Commun*. 13:2690. [PubMed](#)
193. Spiljar M, *et al.* 2021. *Cell Metab*. 33:2231. [PubMed](#)
194. Nabekura T, *et al.* 2020. *Immunity*. 96:52. [PubMed](#)
195. Bae S, *et al.* 2021. *Cell Reports*. 35(11):109264. [PubMed](#)
196. Harvey RE *et al.* 2017. *Endocrinology*. 158(7):2179-2189 . [PubMed](#)
197. Chng S, *et al.* 2016. *Sci Rep*. 6: 23820. [PubMed](#)
198. Denis C, *et al.* 2014. *Nucleic Acids Res*. 42:7370. [PubMed](#)
199. Yu YR, *et al.* 2020. *STAR Protocols*. 11(3):e0150606. [PubMed](#)
200. Riopel M, *et al.* 2019. *Mol Metab*. 20:89. [PubMed](#)
201. Youssif C, *et al.* 2018. *EMBO Mol Med*. 10:e8403. [PubMed](#)
202. Moriyasu T, *et al.* 2018. *PLoS Negl Trop Dis*. 12:e0006197. [PubMed](#)
203. Tham SM, *et al.* 2021. *Biomedicines*. 9:. [PubMed](#)
204. Aggarwal N, *et al.* 2021. *Cell Rep*. 37:110170. [PubMed](#)
205. Zhang L, *et al.* 2021. *Mol Ther*. 29:744. [PubMed](#)

RRID AB_893490 (BioLegend Cat. No. 123113)
 AB_893478 (BioLegend Cat. No. 123114)

Antigen Details

Structure	EGF-TM7 family member, 160 kD glycoprotein
Distribution	Majority of tissue macrophages including peritoneal macrophages, macrophages in lung, gut, thymus and red pulp of spleen, Kuffer cells, Langerhans cells, bone marrow stromal cells, and a subset of dendritic cells
Function	Induction of immunological tolerance
Cell Type	Dendritic cells, Langerhans cells, Macrophages, Tregs
Biology Area	Cell Biology, Immunology, Innate Immunity, Neuroinflammation, Neuroscience
Antigen References	<ol style="list-style-type: none"> 1. Austy JM and Gordon S. 1981. <i>Eur. J. Immunol</i>. 11:805. 2. Hume DA, <i>et al.</i> 1983. <i>J. Exp. Med</i>. 158:1522. 3. Ruedl C, <i>et al.</i> 1996. <i>Eur. J. Immunol</i>. 26:1801.

- McKnight AJ, *et al.* 1996. *J. Biol. Chem.* 271:486.
- Lin HH, *et al.* 2005. *J. Exp. Med.* 201:1615.

Gene ID [13733](#)


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

Brilliant Violet 605™ anti-mouse F4/80, Purified anti-mouse F4/80, Biotin anti-mouse F4/80, FITC anti-mouse F4/80, PE anti-mouse F4/80, PE/Cyanine5 anti-mouse F4/80, PE/Cyanine7 anti-mouse F4/80, APC anti-mouse F4/80, APC/Cyanine7 anti-mouse F4/80, Alexa Fluor® 488 anti-mouse F4/80, Alexa Fluor® 647 anti-mouse F4/80, Pacific Blue™ anti-mouse F4/80, PerCP anti-mouse F4/80, PerCP/Cyanine5.5 anti-mouse F4/80, Alexa Fluor® 700 anti-mouse F4/80, Brilliant Violet 421™ anti-mouse F4/80, Brilliant Violet 510™ anti-mouse F4/80, Alexa Fluor® 594 anti-mouse F4/80, Brilliant Violet 785™ anti-mouse F4/80, Purified anti-mouse F4/80 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse F4/80, Brilliant Violet 650™ anti-mouse F4/80, Brilliant Violet 711™ anti-mouse F4/80, APC/Fire™ 750 anti-mouse F4/80, TotalSeq™-A0114 anti-mouse F4/80, TotalSeq™-B0114 anti-mouse F4/80, TotalSeq™-C0114 anti-mouse F4/80, Spark YG™ 570 anti-mouse F4/80, KIRAVIA Blue 520™ anti-mouse F4/80, Ultra-LEAF™ Purified anti-mouse F4/80, APC/Fire™ 810 anti-mouse F4/80, Spark NIR™ 685 anti-mouse F4/80

Product Data



Thioglycolate-elicited BALB/c mouse peritoneal macrophages stained with BM8 PE/Cyanine7

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587